|
**Overview**: Polycystic Ovary Disease (PCOD) Panel**Introduction**: The Polycystic Ovary Disease (PCOD) Panel is a diagnostic tool designed to screen for polycystic ovarian disease using serum samples. In India, PCOS affects ~20-30 percent of reproductive-age women (higher in urban/obese), causing irregular cycles, hirsutism, infertility, and metabolic complications (diabetes, CVD). High morbidity from under-testing in rural/low-SES women with menstrual irregularity or infertility, limited endocrine labs, delayed lifestyle modification or metformin/OCPs leading to prolonged infertility or endometrial hyperplasia. Per endocrinology practices aligned with ICMR, Endocrine Society of India, and FOGSI guidelines, the test employs spectrophotometry for FSH, LH, prolactin, testosterone, insulin, DHEAS, AMH, and TSH over 1-2 days with high accuracy, valuable for Rotterdam criteria diagnosis (hyperandrogenism, ovulatory dysfunction, polycystic ovaries). This diagnostic falls under hormonal screening and targets women with irregular cycles, hirsutism, or infertility, addressing accurate detection to guide weight loss, OCPs, or ovulation induction. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise PCOS profiling and reducing infertility/metabolic burden. Its serum-based approach ensures reliable multi-hormone assessment.**Other Names**: PCOD Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/endocrinology, compliant with 2025 standards.**Historical Milestone**: PCOS hormonal panel standard; in India, routine in gynecology/endocrinology.**Purpose**: The test assesses 8 parameters including FSH to guide PCOD screening, detect hormonal imbalance, inform therapy.**Test Parameters**: 1. FSH, 2. LH, 3. Prolactin, 4. Testosterone, 5. Insulin, 6. DHEAS, 7. AMH, 8. TSH.**Pretest Condition**: Fasting 10-12 hours recommended; day 2-5 of cycle preferred.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on cycle irregularity, hirsutism.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated PCOS including infertility, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or incorrect cycle day can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High LH/FSH ratio, elevated testosterone/AMH indicate PCOS, necessitating specialist input.**Specialist Consultation**: Gynecologists or endocrinologists should be consulted for management.**Additional Supporting Tests**: Pelvic ultrasound, HOMA-IR for confirmation.**Test Limitations**: Cycle-day dependent; comprehensive approach required.**References**: Indian Journal of Endocrinology 2024, PCOS Studies India 2023. |
